Global Latent TB Testing Market (2025 Edition): Analysis By Test Type (Tuberculin Skin Test (TST), and Interferon Gamma Released Assay (IGRA)), By End User, By Region, By Country: Market Insights and Forecast (2020-2030)

Executive Summary

Azoth Analytics has released a research report titled “Global Latent TB Testing Market (2025 Edition)” which provides a complete analysis of the Global Latent TB Testing industry in terms of market segmentation By Test Type (Tuberculin Skin Test (TST), and Interferon Gamma Released Assay (IGRA)), By End User (Diagnostic Laboratories, Hospitals and Clinics, and Academic and Research Institute), for the historical period of 2020-2023, the estimates of 2024 and the forecast period of 2025-2030.

The report analyses the Latent TB Testing Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, United Kingdom France, Germany, China, South Korea, Australia, Japan, and India). The Global Latent TB Testing market showcased growth at a CAGR of 10.47% during 2020-2023. The market was valued at USD 1991.33 Million in 2023 which is expected to reach USD 4434.05 Million in 2030. Latent TB Testing Market is being propelled by government initiatives and policies, rising awareness and education, and technological advancements in testing methods.The prevalence of TB, especially in high-burden regions, drives the need for effective latent TB testing. As TB remains a global health concern, early detection and management of latent infections become critical for disease control.

The global latent TB testing market is witnessing a surge in multiplex testing capabilities, enabling simultaneous detection of multiple biomarkers associated with latent and active TB. This innovation reduces diagnostic turnaround times and facilitates comprehensive patient management. Furthermore, advancements in molecular diagnostics, such as polymerase chain reaction (PCR)-based assays, are enabling precise detection of latent TB infections by targeting specific genomic sequences of Mycobacterium tuberculosis. These molecular techniques are especially beneficial for diagnosing latent TB in immunocompromised individuals, such as HIV/AIDS patients, where traditional methods may yield inconclusive results.

Point-of-care (POC) testing is another transformative trend gaining traction in the latent TB testing landscape. Portable and user-friendly POC devices empower healthcare providers to conduct rapid testing in remote and resource-limited settings, addressing accessibility challenges in underserved populations. These advancements are particularly crucial in low-income countries, where the burden of latent TB is disproportionately high. Moreover, the miniaturization of diagnostic platforms and the development of battery-operated devices enhance the feasibility of on-the-ground testing initiatives.

Telemedicine and remote diagnostics are reshaping the latent TB testing ecosystem, driven by the COVID-19 pandemic’s emphasis on remote healthcare delivery. Mobile health (mHealth) applications and teleconsultation platforms facilitate virtual screening, symptom monitoring, and follow-up care, reducing the need for in-person visits. This trend not only enhances patient convenience but also expands the reach of TB control programs to geographically dispersed populations.

Furthermore, the latent TB testing market is experiencing a paradigm shift towards personalized medicine, with advancements in genomics and proteomics paving the way for tailored diagnostic and therapeutic approaches. Biomarker-based tests and pharmacogenomic profiling are enabling precise risk stratification and individualized treatment plans, thereby improving patient outcomes and reducing the risk of latent TB progressing to active disease. Additionally, ongoing research into novel biomarkers and immune response pathways promises to unlock further innovations in latent TB diagnostics.

Moreover, the global latent TB testing market is undergoing a profound transformation driven by technological advancements and emerging trends. The integration of next-generation diagnostic tools, automation, AI, POC testing, multiplex capabilities, molecular diagnostics, telemedicine, and personalized medicine underscores the industry’s commitment to combating latent TB through innovative and accessible solutions. These developments not only enhance the effectiveness of latent TB control programs but also contribute to the broader goal of eradicating tuberculosis as a global public health threat.

Scope of the Report:

• The report analyses the Latent TB Testing Market by Value (USD Million).
• The report analyses the Latent TB Testing Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, United Kingdom France, Germany, China, South Korea, Australia, Japan, and India).
• The report presents the analysis of Latent TB Testing Market for the historical period of 2020-2023, the estimated year 2024 and the forecast period of 2025-2030.
• The report analyses the Latent TB Testing Market by Test Type (Tuberculin Skin Test (TST), and Interferon Gamma Released Assay (IGRA)).
• The report analyses the Latent TB Testing Market by End User (Diagnostic Laboratories, Hospitals and Clinics, and Academic and Research Institute).
• The key insights of the report have been presented through the frameworks of SWOT and Porter’s Five Forces Analysis. Also, the attractiveness of the market has been presented by region, by test type, & by end user.
• Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.
• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analyzed in the report are QIAGEN, Sanofi, Abbott Laboratories, Serum Institute of India, F. Hoffmann-La Roche AG, Bio-Rad Laboratories, PerkinElmer Inc., BioMerieux, Becton Dickinson and Co, LIONEX GmbH.